Connection
Adit Ginde to Ritonavir
This is a "connection" page, showing publications Adit Ginde has written about Ritonavir.
|
|
Connection Strength |
|
 |
|
 |
|
1.795 |
|
|
|
-
Molina KC, Ginde AA. Real-world use of nirmatrelvir-ritonavir: who benefits? Lancet Infect Dis. 2023 07; 23(7):765-767.
Score: 0.803
-
Kaizer AM, Shapiro NI, Wild J, Brown SM, Cwik BJ, Hart KW, Jones AE, Pulia MS, Self WH, Smith C, Smith SA, Ng PC, Thompson BT, Rice TW, Lindsell CJ, Ginde AA. Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial. Int J Infect Dis. 2023 Mar; 128:223-229.
Score: 0.792
-
Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Ginde AA. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023 06; 23(6):696-705.
Score: 0.200
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|